Results 111 to 120 of about 198,722 (342)

Targeting BRAF in cancers – from molecular diagnostics to personalized therapy

BioTechnologia
Molecular profiling has become a cornerstone of cancer diagnosis and treatment, with BRAF alterations serving as significant markers across various tumor types.
Zuzanna Pyc, Rafal Rygiel, Dagmara Michalowska, Marcin Ekiert, Izabela Laczmanska   +4 more
doaj   +1 more source

Architecture of autoinhibited and active BRAF/MEK1/14-3-3 complexes

Nature, 2019
RAF family kinases are RAS-activated switches that initiate signalling through the MAP kinase cascade to control cellular proliferation, differentiation and survival1–3.
Eunyoung Park, S. Rawson, Kunhua Li, Byeong-Won Kim, S. Ficarro, Gonzalo Gonzalez-Del Pino, H. Sharif, J. Marto, H. Jeon, M. Eck   +9 more
semanticscholar   +1 more source

Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma

Advanced Science, EarlyView.
CSPG4 is identified as a high‐value, stemness‐associated target in HPV‐negative HNSCC. By implementing rational biophysical engineering, a humanized and charge‐optimized CAR is developed to overcome tonic signaling‐induced exhaustion. This strategy induces a profound transcriptomic shift toward a rejuvenated, stem‐like memory state, significantly ...
Xiang Xu, Shizhen Qiu, Zhitong Wang, Dan Li, Min Chen, Yinying Chu, Guangfei Li, Yi Fang, Changjiang Li, Fang Shi, Peijie He, Haitao Wu, Haopeng Wang, Jian Chen   +13 more
wiley   +1 more source

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours [PDF]

, 2016
Purpose: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the ...
Allen, Rodger, Anthoney, Alan, Banerji, Udai, Bevan, Paul, Boddy, Alan V., Buerkle, Markus, Coyle, Vicky, Cresti, Nicola, Dean, Emma, Drew, Yvette, Evans, T.R. Jefferey, Greystoke, Alastair, Griffin, Melanie J., Jamieson, David, Mala, Carola, Merriman, Mark, Plummer, Ruth, Ranson, Malcolm, Rodgers, Lisa, Sludden, Julieann, Swales, Karen, Wilson, Richard H.   +21 more
core   +2 more sources

Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression

Advanced Science, EarlyView.
This study uncovers a new oncogenic mechanism in melanoma. The transcription factor PATZ1 competes with the architectural protein CTCF for DNA binding, thereby disrupting a specific chromatin loop and silencing the tumor suppressor ZBTB20. This event unleashes the pro‐tumorigenic PMEPA1‐p38‐STAT1 signaling axis, promoting cancer progression.
Chaowei Deng, Shuang Cai, Chen Guo, Shaker Khan, Lefan Liu, Qiong Tian, Zhiyuan Ma, Jian Zhang, Lingyu Zhao   +8 more
wiley   +1 more source

Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma [PDF]

, 2019
Background Patients with malignant melanoma often relapse after treatment with BRAF and/or mitogen‐activated protein kinase kinase (MEK) inhibitors (MEKi) owing to development of drug resistance.
Alexander, M., Chaudhry, B., Edwards, N., Hill, David, Lovat, P.E., Plummer, R., Verykiou, S.   +6 more
core   +1 more source

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Oncotarget, 2014
Almost 50% of metastatic melanoma patients harbor a BRAF(V600) mutation and the introduction of BRAF inhibitors has improved their treatment options. BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. However, most patients develop
SPAGNOLO, FRANCESCO, GHIORZO, PAOLA, Queirolo, P.   +2 more
openaire   +3 more sources

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

Advanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang, Wanyi Xiao, Hongru Shen, Fenge Li, Ting Li, Weihong Zhang, Haotian Liu, Ziwei Gao, Hongyu Wang, Xiubao Ren, Kexin Chen, Xiangchun Li, Jilong Yang   +12 more
wiley   +1 more source

Prognostic and Predictive Role of Lymph Node Count in Stage II Colon Cancer: A Retrospective Analysis of a Japanese Nationwide Cohort

Annals of Gastroenterological Surgery, EarlyView.
This study analyzed over 3500 patients with stage II colon cancer treated with D3 lymphadenectomy, to reassess the prognostic value of number of harvested lymph node and their role in predicting benefit from adjuvant chemotherapy using a Japanese nationwide cohort.
Kozo Kataoka, Akira Ouchi, Kanae Takahashi, Kazuma Ito, Manabu Shiozawa, Kenta Iguchi, Takashi Akiyoshi, Takefumi Yoshida, Masataka Ikeda, Eiji Shinto, Yasuyuki Takamizawa, Yoichi Ajioka, Hirotoshi Kobayashi, Yukihide Kanemitsu   +13 more
wiley   +1 more source

Melanoma expression analysis with Big Data technologies [PDF]

, 2017
Melanoma is a highly immunogenic tumor. Therefore, in recent years physicians have incorporated drugs that alter the immune system into their therapeutic arsenal against this disease, revolutionizing in the treatment of patients in an advanced stage of ...
Aldana-Montes, Jose Francisco, Berciano-Guerrero, Miguel Angel, Fernandez-Rovira, Alicia, Lavado-Valenzuela, Rocio, Navas-Delgado, Ismael   +4 more
core   +2 more sources